非典型抗精神病药齐拉西酮的药代动力学、药效学及临床应用研究进展

Research progress on the pharmacokinetics/pharmacodynamics character and clinical practices of the atypical antipsychotic ziparsidone

齐拉西酮是一个第2代抗精神分裂症药,于2001年经美国食品药品管理局(FDA)批准上市。该药有独特的受体结合特性,从而使临床疗效及安全性有特殊性。本文对近年来该药的药代动力学、药效学及临床应用研究相关文献进行综述,为其临床应用提供参考。

Ziprasidone, as a second - generation antipsychotic, received Food and Drug Administration approval in February 2001. It has a unique receptor profile, and as result that has specificity in its therapeutic effect and its safety. This monograph summarizes the pharmacokinetic / pharmacodynamic （PK/PD） character as well as the efficacy, tolerability, and safety of ziprasidone in the treatment of schizophrenia, schizoaffective disorder, and bipolar mania.